Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.
2.

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S.

Biochem Biophys Res Commun. 1999 Oct 14;264(1):108-11.

PMID:
10527849
3.

Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.

Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V, Clézardin P.

Bone. 2011 Feb;48(2):259-66. doi: 10.1016/j.bone.2010.09.035. Epub 2010 Oct 20.

PMID:
20920623
4.

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.

Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-34. Epub 2006 May 9.

5.

Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.

Räikkönen J, Taskinen M, Dunford JE, Mönkkönen H, Auriola S, Mönkkönen J.

Biochem Biophys Res Commun. 2011 Apr 22;407(4):663-7. doi: 10.1016/j.bbrc.2011.03.070. Epub 2011 Mar 21.

PMID:
21420384
6.

Functional characterization of the Xanthophyllomyces dendrorhous farnesyl pyrophosphate synthase and geranylgeranyl pyrophosphate synthase encoding genes that are involved in the synthesis of isoprenoid precursors.

Alcaíno J, Romero I, Niklitschek M, Sepúlveda D, Rojas MC, Baeza M, Cifuentes V.

PLoS One. 2014 May 5;9(5):e96626. doi: 10.1371/journal.pone.0096626. eCollection 2014.

7.

Farnesyl diphosphate synthase. Altering the catalytic site to select for geranyl diphosphate activity.

Stanley Fernandez SM, Kellogg BA, Poulter CD.

Biochemistry. 2000 Dec 19;39(50):15316-21.

PMID:
11112517
8.
9.

Synthesis and application of a fluorescent substrate analogue to study ligand interactions for undecaprenyl pyrophosphate synthase.

Chen AP, Chen YH, Liu HP, Li YC, Chen CT, Liang PH.

J Am Chem Soc. 2002 Dec 25;124(51):15217-24.

PMID:
12487597
10.

Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.

De Schutter JW, Zaretsky S, Welbourn S, Pause A, Tsantrizos YS.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5781-6. doi: 10.1016/j.bmcl.2010.07.133. Epub 2010 Aug 11.

PMID:
20801032
11.

Purification of geranylgeranyl diphosphate synthase from bovine brain.

Sagami H, Morita Y, Korenaga T, Ogura K.

Acta Biochim Pol. 1994;41(3):293-302.

12.

Synthesis of (S)-isoprenoid thiodiphosphates as substrates and inhibitors.

Phan RM, Poulter CD.

J Org Chem. 2001 Oct 5;66(20):6705-10.

PMID:
11578224
13.

Structural characterization of substrate and inhibitor binding to farnesyl pyrophosphate synthase from Pseudomonas aeruginosa.

Schmidberger JW, Schnell R, Schneider G.

Acta Crystallogr D Biol Crystallogr. 2015 Mar;71(Pt 3):721-31. doi: 10.1107/S1399004715001121. Epub 2015 Feb 26.

14.

Thermodynamic evaluation of the binding of bisphosphonates to human farnesyl pyrophosphate synthase.

Kawasaki Y, Sekiguchi M, Kawasaki M, Hirakura Y.

Chem Pharm Bull (Tokyo). 2014;62(1):77-83. Epub 2013 Oct 29.

15.

Synthesis and enzymatic studies of bisubstrate analogues for farnesyl diphosphate synthase.

Ramamoorthy G, Pugh ML, Tian BX, Phan RM, Perez LB, Jacobson MP, Poulter CD.

J Org Chem. 2015 Apr 17;80(8):3902-13. doi: 10.1021/acs.joc.5b00202. Epub 2015 Mar 26.

PMID:
25734506
16.

The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.

Tsoumpra MK, Muniz JR, Barnett BL, Kwaasi AA, Pilka ES, Kavanagh KL, Evdokimov A, Walter RL, Von Delft F, Ebetino FH, Oppermann U, Russell RG, Dunford JE.

Bone. 2015 Dec;81:478-86. doi: 10.1016/j.bone.2015.08.020. Epub 2015 Aug 28.

17.

Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.

Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W.

ChemMedChem. 2006 Feb;1(2):267-73.

PMID:
16892359
18.

Molecular characterization of farnesyl pyrophosphate synthase from Bacopa monniera by comparative modeling and docking studies.

Vishwakarma RK, Patel KA, Sonawane P, Singh S, Ruby, Kumari U, Agrawal DC, Khan BM.

Bioinformation. 2012;8(22):1075-81. doi: 10.6026/97320630081075. Epub 2012 Nov 13.

19.

Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.

Dunford JE, Kwaasi AA, Rogers MJ, Barnett BL, Ebetino FH, Russell RG, Oppermann U, Kavanagh KL.

J Med Chem. 2008 Apr 10;51(7):2187-95. doi: 10.1021/jm7015733. Epub 2008 Mar 8.

PMID:
18327899
20.

The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates.

Ling Y, Li ZH, Miranda K, Oldfield E, Moreno SN.

J Biol Chem. 2007 Oct 19;282(42):30804-16. Epub 2007 Aug 27.

Items per page

Supplemental Content

Write to the Help Desk